AFT Pharmaceuticals Ltd
June 23, 2026
Theater 1
Type: Company Presentation
Focus Area:
Multiple Therapeutics
Commercial company operating in 85 countries around the globe with an extensive R&D portfolio - presently 9 projects
Company HQ City:
Auckland
Company HQ State:
Auckland
Company HQ Country:
New Zealand
Year Founded:
1997
Lead Product in Development:
Maxigesic, Crystaderm, Pascomer, Novel IV Therapy, Fridge Free IV formulations (12 drugs), Antibiotic Eye Drop for drug resistant eye infections, Topical Strawberry Birthmarks Tx, Topical Keloid Scars Tx,
CEO
Hartley Atkinson
Development Phase of Lead Product
Phase III
Number of Unlicensed Products Looking for Licensing
Up to 8
Exchange
NZX
Ticker
AFT.NZ
When you expect your next catalyst update?
By end of 2026 calendar year
What is your next catalyst (value inflection) update?
Completion key clinical studies
Primary Speaker
)
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}